Side-by-side research comparison of Liraglutide and Retatrutide across our PubMed, ClinicalTrials.gov, and EuropePMC corpus. No direct head-to-head trials in our corpus — this comparison synthesizes indirect evidence across 377 Liraglutide studies and 67 Retatrutide studies.
| Liraglutide | Retatrutide | |
|---|---|---|
| Drug class | glp 1 agonist | glp 1 agonist, gip agonist, glucagon agonist |
| Studies in corpus | 377 | 67 |
| Highest evidence tier | rct | meta analysis |
| Evidence tier mix | rct · 8 cohort · 2 review · 2 in vitro · 2 preclinical animal · 1 | review · 16 preclinical animal · 3 other · 11 rct · 16 meta analysis · 4 |
| Studies with explicit sample size | 5 | 2 |
| Head-to-head studies in corpus | 0 — indirect comparison only | |
Beyond the literature: here's what third-party Certificate-of-Analysis records (Janoshik, BCC, Auxlabs) say about real Liraglutide and Retatrutide batches we've tested. Aggregate, public data — cross-reference against the studies below.
We tested 9 Liraglutide batches across 4 manufacturers, 99.58% avg purity.
We tested 20061 Retatrutide batches across 2698 manufacturers, 99.66% avg purity.
We hold deeper lab coverage on Retatrutide (20061 batches tested). Retatrutide edges ahead on average measured purity (99.58% vs 99.66%) — a narrow gap; weigh it against failed-batch and underdose counts above.
Looking for vendor-level purity, endotoxin, and HPLC data on Liraglutide or Retatrutide? TitrateLab tracks Certificate-of-Analysis records from the major peptide labs (Janoshik, BCC, Auxlabs) alongside the research above. Cross-reference vendor batches against the studies on this page.